1. Home
  2. SCHL vs URGN Comparison

SCHL vs URGN Comparison

Compare SCHL & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCHL
  • URGN
  • Stock Information
  • Founded
  • SCHL 1920
  • URGN 2004
  • Country
  • SCHL United States
  • URGN United States
  • Employees
  • SCHL N/A
  • URGN N/A
  • Industry
  • SCHL Books
  • URGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • SCHL Consumer Discretionary
  • URGN Health Care
  • Exchange
  • SCHL Nasdaq
  • URGN Nasdaq
  • Market Cap
  • SCHL 478.8M
  • URGN 463.2M
  • IPO Year
  • SCHL 1987
  • URGN 2017
  • Fundamental
  • Price
  • SCHL $17.02
  • URGN $4.84
  • Analyst Decision
  • SCHL
  • URGN Strong Buy
  • Analyst Count
  • SCHL 0
  • URGN 8
  • Target Price
  • SCHL N/A
  • URGN $27.92
  • AVG Volume (30 Days)
  • SCHL 248.7K
  • URGN 2.6M
  • Earning Date
  • SCHL 07-17-2025
  • URGN 05-12-2025
  • Dividend Yield
  • SCHL 4.63%
  • URGN N/A
  • EPS Growth
  • SCHL N/A
  • URGN N/A
  • EPS
  • SCHL 0.65
  • URGN N/A
  • Revenue
  • SCHL $1,592,100,000.00
  • URGN $91,871,000.00
  • Revenue This Year
  • SCHL $3.42
  • URGN $35.06
  • Revenue Next Year
  • SCHL $5.47
  • URGN $112.94
  • P/E Ratio
  • SCHL $26.49
  • URGN N/A
  • Revenue Growth
  • SCHL N/A
  • URGN 8.98
  • 52 Week Low
  • SCHL $15.77
  • URGN $3.42
  • 52 Week High
  • SCHL $38.77
  • URGN $20.70
  • Technical
  • Relative Strength Index (RSI)
  • SCHL 41.60
  • URGN 33.12
  • Support Level
  • SCHL $16.81
  • URGN $3.61
  • Resistance Level
  • SCHL $17.85
  • URGN $4.25
  • Average True Range (ATR)
  • SCHL 0.67
  • URGN 0.83
  • MACD
  • SCHL -0.10
  • URGN -0.31
  • Stochastic Oscillator
  • SCHL 10.08
  • URGN 17.09

About SCHL Scholastic Corporation

Scholastic Corp is an American publishing and education media company that focuses on books and educational material for schools, teachers, parents, and children. It creates print, digital, and audiobooks, learning materials and programs, classroom magazines, and other products that support children's learning and reading both at home and at school. The company also owns rights to various books, including Harry Potter, Dog Man, and The Hunger Games among others. It has three reportable segments Children's Book Publishing and Distribution, Education Solutions, and International. The majority of its revenue is from the Children's Book Publishing and Distribution segment.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: